Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
The fresh funds will be used to enhance customer relationships, expand operations and develop state-of-the-art service
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
The inspection was concluded with zero observations
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024
Indoco Remedies is addressing the observations comprehensively and will respond to the USFDA within the stipulated timeframe
Subscribe To Our Newsletter & Stay Updated
